Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-T therapy for CD19-positive B-cell malignancies
ChiCTR-OIC-17013633Phase 2Recruiting
- Sponsor
- Shenzhen Inno Immune
- Start
- Sep 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-transduced T cells in B-cell malignancy, B cell acute lymphoblastic leukemia (B-ALL) and malignant B-cell neoplasm, sponsored by Shenzhen Inno Immune. Primary endpoint: Safety and feasibility of anti-CD19 CAR-transduced T cells. Started Sep 2017; status: recruiting.
02
Drugs
anti-CD19 CAR-transduced T cells
03
Conditions
B-cell malignancyB cell acute lymphoblastic leukemia (B-ALL)malignant B-cell neoplasm
Beyond the preview
Go deeper on ChiCTR-OIC-17013633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013633.